Loading...
NPI 1881894566 · New York, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Irene Barbazetto is a ophthalmology physician provider located in New York, New York. This profile covers 17 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Irene Barbazetto |
| Address | 950 Third Avenue |
| City | New York |
| State | NY |
| ZIP | 10022 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | July 20, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.2M |
| Medicaid | $86.9K |
This provider is overwhelmingly Medicare-focused: reported Medicare revenue is $3.2M versus Medicaid revenue of $86.9K, so Medicaid represents a very small share of billed revenue and the practice is effectively single-payer dependent on Medicare for scale. That concentration implies reimbursement or policy changes on the Medicare side would have an outsized impact on overall revenue.
Medicare revenue is highly concentrated in intravitreal drug administration and related retinal services: the precomputed top-3 Medicare codes account for 74.7% of Medicare revenue, led by J0178 which alone represents 54.6% of the provider's Medicare revenue. J0178 (aflibercept) is the dominant single revenue driver, with J2777 (faricimab) and J3490 (unclassified drugs) also contributing materially, indicating a service line centered on anti-VEGF and other intravitreal therapies.
The mix of high-revenue injection codes plus very high volume diagnostic codes points to an operational model built around frequent follow-up visits, imaging, and injections. The provider bills large volume for established patient exams and retinal imaging (92012: 2.3K claims, $178.1K revenue, rank #49 of 17177 — labeled an extreme outlier; 92134: 2.8K claims, $98.6K revenue, rank #482 of 26868 — extreme outlier; 92250: 919 claims, $30.3K revenue, rank #324 of 25087 — extreme outlier). This pattern is consistent with a high-throughput ophthalmology/retina clinic that pairs frequent diagnostics with intravitreal therapy.
Although J0178 is the largest revenue source, its national competitive standing is described as "typical, unremarkable volume" (J0178: 2.6K claims, $1.8M Medicare revenue, rank #304 of 3204, 91th percentile), while several diagnostic and imaging codes are extreme outliers versus national peers. In other words, the practice is not nationally dominant for aflibercept injection volumes but is an outlier for clinic visit and imaging throughput, suggesting local or practice-level intensity rather than exceptional national market share for drug administration.
Medicaid billing mirrors the Medicare pattern but at much smaller scale and with even greater concentration: the precomputed top-3 Medicaid codes account for 94.9% of Medicaid revenue, with J0178 alone representing 72.8% of the provider's Medicaid revenue. J0178 for Medicaid shows modest in-state standing (157 claims, $63.4K revenue, rank #64 of 101 in-state, 37th percentile), indicating the provider is not a leading Medicaid aflibercept performer within New York despite that code driving most of their Medicaid receipts.
The provider reports a non-specific but material Medicare revenue line under J3490 (192 claims, $309.5K revenue, $1,612 avg paid/claim, rank #352 of 2838, 87th percentile), which suggests occasional use of unclassified drug billing that contributes meaningful revenue. Because J3490 payments are high on a per-claim basis, this category represents a notable portion (9.6%) of Medicare revenue and should be considered when evaluating drug-revenue risk and contract design.
Tenure is long: the NPI was enumerated on 2007-07-20 (~19 years ago), indicating an established practice and sustained presence in the market. That longevity, coupled with extreme outlier volumes for intermediate exams and retinal imaging, supports the interpretation of a stable, high-throughput ophthalmology/retina practice rather than a newly scaled operation.
From a payer contracting and utilization-management perspective, the combination of very high Medicare volume in imaging and established-patient visits (92012, 92134, 92250 labeled extreme outliers) plus concentrated drug revenue (top-3 Medicare codes = 74.7%) highlights the clinic as a high-utilization partner for retinal care. Given Medicaid is only $86.9K in lifetime revenue and the provider ranks modestly in-state for key Medicaid codes, payers should treat Medicare utilization patterns as the primary signal for clinical and network strategy while recognizing Medicaid exposure is limited.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,550 | $690 | $1.8M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 11,820 | $30 | $342.8K |
| J3490 | Unclassified drugs | 190 | $1,610 | $309.5K |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,060 | $180 | $192.9K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,620 | $110 | $181.6K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 2,280 | $80 | $178.1K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,820 | $40 | $98.6K |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 480 | $120 | $57.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 460 | $100 | $45.5K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 920 | $30 | $30.3K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 23 | 230 | 560 | $690 | $693K |
| J2777 | 36 | 120 | 7,740 | $30 | $364.9K |
| J2778 | 14 | 70 | 510 | $180 | $131.6K |
| J2781 | 23 | 40 | 520 | $120 | $75.1K |
| 67028 | 33 | 300 | 400 | $100 | $65.9K |
| J3490 | 14 | 120 | 60 | $470 | $50.8K |
| 92014 | 487 | 2,220 | 160 | $100 | $29.3K |
| 92012 | 8 | 1,640 | 100 | $70 | $17.4K |
| 92235 | 156 | 190 | 60 | $120 | $14.1K |
| 92134 | 28 | 1,580 | 90 | $30 | $11.2K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 160 | $400 | $63.4K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 580 | $20 | $13.4K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 10 | $420 | $5.9K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 120 | $20 | $2.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 210 | $10 | $1.4K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 20 | $10 | $220 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 64 | 100 | 280 | $650 | $369.9K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 15 | 20 | 120 | $720 | $173.2K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 939 | 1,460 | 310 | $60 | $88.1K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 116 | 260 | 420 | $70 | $65.6K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 1,336 | 1,490 | 340 | $40 | $48.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 442 | 730 | 370 | $20 | $30K |
Other providers in the same ZIP code as Irene Barbazetto, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Ali Aboufares | NY | Interventional Cardiology Physician | $1.3M | $2.1M |
| Wayne Fuchs | NY | Ophthalmology Physician | $1.7M | $0 |
| Robert Klein | NY | Ophthalmology Physician | $735.9K | $0 |
| Brian Apatoff | NY | Neurology Physician | $708.5K | $0 |
| Ramon Valderrama | NY | Neurology Physician | $293.2K | $297.4K |
| David Bolon | NY | Cardiovascular Disease Physician | $508.4K | $350 |
| Roy Geronemus | NY | Specialist | $472.2K | $0 |
| Brian Gelbman | NY | Pulmonary Disease Physician | $426.3K | $0 |
| Alan Manevitz | NY | Psychiatry Physician | $397.9K | $0 |
| Clark Huang | NY | Specialist | $390K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.